{
  "id": "5a7373f63b9d13c708000008",
  "type": "factoid",
  "question": "Which disease is treated with Fexinidazole?",
  "ideal_answer": "Oral fexinidazole is effective for late-stage human african  trypanosomiasis.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/29113731",
    "http://www.ncbi.nlm.nih.gov/pubmed/22301556",
    "http://www.ncbi.nlm.nih.gov/pubmed/28552771",
    "http://www.ncbi.nlm.nih.gov/pubmed/27748443",
    "http://www.ncbi.nlm.nih.gov/pubmed/25409760",
    "http://www.ncbi.nlm.nih.gov/pubmed/25694261",
    "http://www.ncbi.nlm.nih.gov/pubmed/21200426",
    "http://www.ncbi.nlm.nih.gov/pubmed/21911566",
    "http://www.ncbi.nlm.nih.gov/pubmed/24535888",
    "http://www.ncbi.nlm.nih.gov/pubmed/24841257",
    "http://www.ncbi.nlm.nih.gov/pubmed/27611920",
    "http://www.ncbi.nlm.nih.gov/pubmed/22539226",
    "http://www.ncbi.nlm.nih.gov/pubmed/23133682"
  ],
  "snippets": [
    {
      "text": "n the search for new therapeutics, the repurposing of the broad-spectrum antiprotozoal drug fexinidazole has completed Phase III trials with the anticipation that it will be the first oral treatment for HAT. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28552771",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29113731",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Therefore, we aimed to assess the safety and efficacy of an oral regimen of fexinidazole (a 2-substituted 5-nitroimidazole with proven trypanocidal activity) versus nifurtimox eflornithine combination therapy in patients with late-stage g-HAT.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29113731",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "INTERPRETATION: Our findings show that oral fexinidazole is effective and safe for the treatment of T b gambiense infection compared with nifurtimox eflornithine combination therapy in late-stage HAT patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29113731",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "AIM: Fexinidazole (FEX) is a nitroimidazole being developed as a new trypanocide treatment for human African trypanosomiasis/sleeping sickness. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27611920",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We also observed that fexinidazole and fexinidazole sulfone are more effective than benznidazole and nifurtimox as curative treatments, particularly for acute stage infections, most likely as a result of the higher and more prolonged exposure of the sulfone derivative.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27748443",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Specifically, the authors review the nitroimidazole compound fexinidazole, which is one of the few drugs which have reached Phase II trials. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25409760",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "New tools considered include tiny targets for tsetse fly control, use of rapid diagnostic tests and oral treatment with fexinidazole or oxaboroles. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25694261",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Fexinidazole metabolites were effective in treating T. cruzi in a mouse model of acute infection, with cure rates superior to those achieved with either fexinidazole itself or benznidazole.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24841257",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Fexinidazole treatment was also shown to reduce myocarditis in all animals infected with VL-10 or Colombian resistant T. cruzi strains, although parasite eradication was not achieved in all treated animals at the tested doses.<br><b>CONCLUSIONS</b>: Fexinidazole is an effective oral treatment of acute and chronic experimental CD caused by benznidazole-susceptible, partially resistant, and resistant T. cruzi.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23133682",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Fexinidazole is moderately active in vitro against African trypanosomes (IC\u2085\u2080 against laboratory strains and recent clinical isolates ranged between 0.16 and 0.93 \u00b5g/mL) and oral administration of fexinidazole at doses of 100 mg/kg/day for 4 days or 200 mg/kg/day for 5 days cured mice with acute and chronic infection respectively, the latter being a model for the advanced and fatal stage of the disease when parasites have disseminated into the brain.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21200426",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Fexinidazole: a potential new drug candidate for Chagas disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23133682",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "BACKGROUND: New safe and effective treatments for Chagas disease (CD) are urgently needed.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23133682",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Antitrypanosomal activity of fexinidazole metabolites, potential new drug candidates for Chagas disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24841257",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Determination of an optimal dosing regimen for fexinidazole, a novel oral drug for the treatment of human African trypanosomiasis: first-in-human studies.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24535888",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Here, we report that fexinidazole, a drug currently in phase 1 clinical trials for treating African trypanosomiasis, shows promise for treating visceral leishmaniasis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22301556",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS Fexinidazole is an effective oral treatment of acute and chronic experimental CD caused by benznidazole-susceptible, partially resistant, and resistant T. cruzi.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23133682",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Fexinidazole, a 2-subsituted 5-nitroimidazole drug candidate rediscovered following extensive compound mining by the Drugs for Neglected Diseases initiative and currently in Phase I clinical study for the treatment of human African trypanosomiasis, was evaluated in experimental models of acute and chronic CD caused by different strains of Trypanosoma cruzi.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23133682",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Therefore, we aimed to assess the safety and efficacy of an oral regimen of fexinidazole (a 2-substituted 5-nitroimidazole with proven trypanocidal activity) versus nifurtimox eflornithine combination therapy in patients with late-stage g-HAT.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29113731",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "INTERPRETATION Our findings show that oral fexinidazole is effective and safe for the treatment of T b gambiense infection compared with nifurtimox eflornithine combination therapy in late-stage HAT patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29113731",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Fexinidazole is a 5-nitroimidazole drug currently in clinical development for the treatment of human sleeping sickness (human African trypanosomiasis [HAT]), caused by infection with species of the protozoan parasite Trypanosoma brucei.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21911566",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In the search for new therapeutics, the repurposing of the broad-spectrum antiprotozoal drug fexinidazole has completed Phase III trials with the anticipation that it will be the first oral treatment for HAT.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28552771",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND AND OBJECTIVES Fexinidazole is a 5-nitroimidazole recently included in a clinical efficacy trial as an oral drug for the treatment of human African trypanosomiasis (HAT).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24535888",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Fexinidazole, a 2-substituted 5-nitroimidazole rediscovered by the Drugs for Neglected Diseases initiative (DNDi) after extensive compound mining of public and pharmaceutical company databases, has the potential to become a short-course, safe and effective oral treatment, curing both acute and chronic HAT.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22539226",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Fexinidazole: a potential new drug candidate for Chagas disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23133682",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Antitrypanosomal activity of fexinidazole metabolites, potential new drug candidates for Chagas disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24841257",
      "beginSection": "title",
      "endSection": "title"
    }
  ],
  "concepts": [
    "http://www.biosemantics.org/jochem#4257906"
  ],
  "exact_answer": "human african  trypanosomiasis"
}